PONTE
VEDRA, Fla., Aug. 14,
2024 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a biopharmaceutical company developing
tecarfarin, a late-stage, next-generation Vitamin K Antagonist
(VKA) oral and reversible anticoagulant (blood thinner) designed to
prevent heart attacks, strokes, and deaths due to blood clots in
patients with implanted cardiac devices and those with rare
cardiovascular conditions, will participate in the following
upcoming conferences that will be available to investors by
webcast.
At the Sidoti and Investor Summit conferences, management will
also participate in one-on-one institutional investor meetings. To
request a meeting with management, please contact your conference
representative or the Company's investor relations team at
cvkd@lythampartners.com.
Sidoti Micro-cap Virtual Conference
Cadrenal
Chief Medical Officer, Dr. Douglas Losordo,
will present highlights of the Company's pipeline progress at
the Sidoti Micro-cap Virtual Conference on
Thursday, August 15, 2024, at
2:30 p.m. ET. The webcast can be accessed by visiting
the investor relations section of the Company's website at
https://www.cadrenal.com/investors/ or accessed
here. A replay of the presentation will also be available via
these sites.
Summer 2024 Investor Summit
Cadrenal Chief
Executive Officer, Quang
Pham, will present an overview of the Company and its
lead candidate tecarfarin at the Summer 2024
Investor Summit Virtual Conference on Tuesday, August 20, 2024 at 3 p.m.
ET. The webcast can be accessed by visiting the investor relations
section of the Company's website at
https://www.cadrenal.com/investors/. A replay of
the presentation will also be available online.
Emerging Growth Conference
Cadrenal Chief
Executive Officer, Quang
Pham, will deliver an update presentation during
the Emerging Growth Conference on Wednesday, August 21, 2024, at 3:55
p.m. ET. The webcast can be accessed by visiting the investor
relations section of the Company's website at
https://www.cadrenal.com/investors/ or accessed
here. A replay of the presentation will also be available at
these sites.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin for unmet needs in
anticoagulation therapy. Tecarfarin is a late-stage novel oral and
reversible anticoagulant (blood thinner) to prevent heart attacks,
strokes, and deaths due to blood clots in patients with implanted
cardiac devices and those with rare cardiovascular conditions.
Tecarfarin has orphan drug designation for the prevention of
thrombosis and thromboembolism in patients with ventricular assist
devices. Tecarfarin also has orphan drug and fast-track
designations from the FDA for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage kidney disease and atrial fibrillation. Cadrenal is also
pursuing additional regulatory strategies for unmet needs in
anticoagulation therapy for patients with thrombotic
antiphospholipid syndrome (APS). Tecarfarin is specifically
designed to leverage a different metabolism pathway than the oldest
and most commonly prescribed Vitamin K Antagonist (warfarin).
Tecarfarin has been evaluated in 11 human clinical trials and more
than 1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease.
For more information, please
visit: www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-present-at-upcoming-investor-conferences-302221590.html
SOURCE Cadrenal Therapeutics, Inc.
